Key facts
- It has raised $1.7M; the latest was Later Stage VC in Sep 2024.
- Notable investors include Bpifrance, Investessor, Key Ventures, Matwin, Paris Biotech Sante — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Seekyo
- ·The full record, as it builds
Funding rounds
No funding rounds for Seekyo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Seekyo
Developer of a tumor microenvironment targeting smart chemotherapy designed to provide cancer patients with efficient treatment without adverse effects. The company's chemotherapy is designed with smart drugs that selectively target the microenvironment to safely transport powerful anti-cancer agents throughout the body, enabling cancer patients to get harmless, efficient, and selective cell treatment.
- Sector
- Healthcare
- HQ
- Poitiers, France
- Founded
- 2018
- Employees
- 8
- Website
- seekyo-therapeutics.com/
- Ownership
- Privately Held (backing)
Seekyo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Seekyo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Seekyo in its N-PORT filings yet. We sweep new filings monthly.